Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

ENDRA Life Sciences Inc. (NDRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "ENDRA Life Sciences Reports Second Quarter 2023 Financial Results and Provides a Business Update",
"# # # 3"
08/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
07/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/25/2023 8-K Quarterly results
07/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "ENDRA Life Sciences Announces Adjournment of 2023 Annual Meeting of Stockholders to July 25, 2023"
07/06/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/24/2023 ARS Form ARS - Annual Report to Security Holders:
05/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/02/2023 8-K Quarterly results
04/28/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/28/2023 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
04/28/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/18/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
04/18/2023 8-K Quarterly results
04/18/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
03/16/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/16/2023 10-K Annual Report for the period ended December 31, 2022
03/10/2023 SC 13G bryan michael sr reports a 6.1% stake in ENDRA LIFE SCIENCES, INC.
02/01/2023 4 Basenese Lou (Director) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 6,746 options @ $4.02, valued at $27.1k
02/01/2023 4 Tokman Alexander Y (Director) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 9,621 options @ $4.02, valued at $38.7k
02/01/2023 4 Harsh Michael (Director) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 9,634 options @ $4.02, valued at $38.7k
02/01/2023 4 DIGIANDOMENICO ANTHONY (Director) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 9,621 options @ $4.02, valued at $38.7k
02/01/2023 4 Pestrikova Irina (Senior Director, Finance) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 8,000 options @ $4.02, valued at $32.2k
02/01/2023 4 Thornton Michael Milos (Chief Technology Officer) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 68,066 options @ $4.02, valued at $273.6k
02/01/2023 4 Michelon Francois Roger (CEO) has filed a Form 4 on ENDRA Life Sciences Inc.
Txns: Granted 69,531 options @ $4.02, valued at $279.5k
12/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/19/2022 8-K Quarterly results
12/13/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/08/2022 8-K Quarterly results
12/02/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy